Teva Pharmaceutical Industries has withdrawn its appeal of a US district court ruling from last summer that upheld Merck & Co's compound patent on its top-selling asthma drug, Singulair (montelukast sodium), according to court documents. Merck is expected to maintain a hold on its franchise in the US until 2012.
Teva Pharmaceutical Industries has withdrawn its appeal of a US district court ruling from last summer that upheld Merck & Co's compound patent on its top-selling asthma drug, Singulair (montelukast sodium), according to court documents. Merck is expected to maintain a hold on its franchise in the US until 2012.
In August, a federal judge in the US District Court for the District of New Jersey upheld the validity of...
With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.
The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.
After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.
Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.
IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.
The osteogenesis imperfecta drug stumbled in a second interim analysis.
The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.
